Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

Core Insights - Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company focused on developing treatments for neuropsychiatric disorders, with a lead drug candidate BNC210 targeting social anxiety disorder and post-traumatic stress disorder [2][4] Company Overview - Neuphoria is advancing BNC210, an oral selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, designed for acute and chronic treatment of anxiety disorders [2] - The company has a strategic partnership with Merck & Co., Inc. for two drugs in early-stage clinical trials aimed at cognitive deficits in Alzheimer's disease and other CNS conditions [2] - Neuphoria's pipeline includes next-generation α7 nicotinic acetylcholine receptor programs and Kv3.1/3.2 preclinical programs, both in lead optimization development [2] Upcoming Events - Neuphoria will present a pharmacokinetic/pharmacodynamic analysis of the BNC210 Attune Phase 2b dataset at the ASCP 2025 Annual Meeting, scheduled for May 28, 2025 [4]